Production (Stage)
X4 Pharmaceuticals, Inc.
XFOR
$3.10
-$0.13-4.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.60M | -37.45M | -16.76M | 17.63M | -128.91M |
| Total Depreciation and Amortization | 1.21M | 796.00K | 585.00K | 422.00K | 354.00K |
| Total Amortization of Deferred Charges | 827.00K | 856.00K | 903.00K | 952.00K | 958.00K |
| Total Other Non-Cash Items | -123.61M | -97.78M | -106.50M | -132.78M | 22.19M |
| Change in Net Operating Assets | -2.70M | 2.68M | -3.88M | 1.32M | 1.82M |
| Cash from Operations | -109.67M | -130.90M | -125.65M | -112.45M | -103.60M |
| Capital Expenditure | -267.00K | -326.00K | -320.00K | -236.00K | -110.00K |
| Sale of Property, Plant, and Equipment | 105.00M | 105.00M | 105.00M | 105.00M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.56M | -37.68M | -33.90M | -23.21M | -20.09M |
| Cash from Investing | 69.17M | 66.99M | 70.78M | 81.55M | -20.20M |
| Total Debt Issued | 20.00M | 20.00M | 20.00M | 42.50M | 22.50M |
| Total Debt Repaid | -- | -- | 0.00 | -764.00K | -764.00K |
| Issuance of Common Stock | 294.00K | 294.00K | 256.00K | 256.00K | 68.99M |
| Repurchase of Common Stock | -- | -- | -- | -281.00K | -281.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -250.00K | 193.00K |
| Cash from Financing | 20.29M | 20.29M | 20.26M | 41.46M | 90.64M |
| Foreign Exchange rate Adjustments | -25.00K | -156.00K | 215.00K | -22.00K | -10.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.23M | -43.77M | -34.40M | 10.54M | -33.16M |